SynthesisBMC infectious diseases2025
Neurological manifestations of Mpox virus during the recent global outbreak: a systematic review.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Beyond the neuron: the role of glial cells in viral neuropathogenesis.Journal of virology · 2026Review
- Recent advances in Mpox across innate immunity, evasion, and clinical outcomes.Communications biology · 2026Review
- MPXV replication and drug resistance in CNS of advanced HIV case at autopsy.Research square · 2026Article
- Diagnostic Advances and Public Health Challenges for Monkeypox Virus: Clade-Specific Insight and the Urgent Need for Rapid Testing in Africa.Diagnostics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMpox is a zoonotic infection caused by the Mpox virus (MPXV), an Orthopoxvirus known to cause fever, lymphadenopathy, mucocutaneous lesions, and some systemic complications. With the recent global outbreak, an increasing number of neurological manifestations have been reported. This systematic review aims to assess and summarize the neurological manifestations associated with Mpox virus infection, highlighting its prevalence, frequency, and clinical impact.
methodsStudies that included data from recent outbreaks, published between May 2022 to January 2025 that reported neurological manifestations in patients infected by Mpox were systematically reviewed using the PRISMA (Preferred Reporting Items for Systematic Review and Meta-Analysis) statement.
resultsOur systematic review included data from 20 studies encompassing data from 2,245 individuals across multiple regions. Neurological manifestations ranged from common symptoms such as fatigue (32.6%), myalgia (29.7%), and headache (29.2%) to severe complications like encephalitis (0.23%), encephalomyelitis (0.23%), transverse myelitis (0.09%), Guillain-Barré Syndrome (0.045%), and Parsonage-Turner Syndrome (0.045%). Autonomic nervous system involvement, including bowel and bladder incontinence, was reported in 0.26% of cases. Severe cases required immunomodulatory therapies such as corticosteroids, intravenous immunoglobulin (IVIG), and antiviral treatments. Recovery varied, from a few weeks, with some patients experiencing prolonged symptoms lasting up to 32 weeks, and a few reporting persistent deficits.
conclusionThis systematic review highlights the wide spectrum of neurological complications associated with Mpox infection, ranging from mild symptoms to severe, debilitating conditions. While most patients experienced resolution of symptoms with appropriate management, a subset developed long-term deficits, underscoring the need for vigilant monitoring and early intervention. Given the increasing global incidence of Mpox, healthcare professionals must be aware of its potential neurological impact to ensure timely diagnosis and effective treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.